LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144 (Supplement 1), p.4822-4822
Main Authors: Sheng, Lingshuang, Yan, Zixun, Wang, Li, Wu, Wen, Zhang, Yilun, Shen, Rong, Cao, Weiguo, Li, Lei, Chen, Sheng, Jiang, Xufeng, Yi, Hongmei, Song, Qi, Cheng, Shu, Xu, Pengpeng, Yang, Xuanming, Zhu, Yuxiang, Xu, Xikang, Wang, Fuzhe, Li, Jianyong, Zhao, Wei Li
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 4822
container_issue Supplement 1
container_start_page 4822
container_title Blood
container_volume 144
creator Sheng, Lingshuang
Yan, Zixun
Wang, Li
Wu, Wen
Zhang, Yilun
Shen, Rong
Cao, Weiguo
Li, Lei
Chen, Sheng
Jiang, Xufeng
Yi, Hongmei
Song, Qi
Wang, Li
Cheng, Shu
Xu, Pengpeng
Yang, Xuanming
Zhu, Yuxiang
Xu, Xikang
Wang, Fuzhe
Li, Jianyong
Zhao, Wei Li
description
doi_str_mv 10.1182/blood-2024-198296
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2024_198296</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1182_blood_2024_198296</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1182_blood_2024_1982963</originalsourceid><addsrcrecordid>eNqdj0tOwzAURS0EEuGzAGZvCBKmz27aJszaAMogilDIhJFlGocEnDiy00reA4umH1bA6N7BPbo6hNwwfGAs4pMPbUxFOfKQsjji8fyEBGzGI4rI8ZQEiDinYbxg5-TCuS9EFk75LCA_2Tvi4h4k5GarNCz7saXJE0dIlgUtIVFaQ9koKwcPtbFQKC0Hpyo49NrK9Wish9VxmZuepqb6_G57yHw3NKaTcFtMCljRPM3uHneM2-jRQW1Nt3t9baRTwOBt3FT-ipzVUjt1_ZeXhL08l0lK19Y4Z1UtBtt20nrBUOy1xUFb7LXFUXv6H-YXC0penw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study</title><source>ScienceDirect®</source><creator>Sheng, Lingshuang ; Yan, Zixun ; Wang, Li ; Wu, Wen ; Zhang, Yilun ; Shen, Rong ; Cao, Weiguo ; Li, Lei ; Chen, Sheng ; Jiang, Xufeng ; Yi, Hongmei ; Song, Qi ; Wang, Li ; Cheng, Shu ; Xu, Pengpeng ; Yang, Xuanming ; Zhu, Yuxiang ; Xu, Xikang ; Wang, Fuzhe ; Li, Jianyong ; Zhao, Wei Li</creator><creatorcontrib>Sheng, Lingshuang ; Yan, Zixun ; Wang, Li ; Wu, Wen ; Zhang, Yilun ; Shen, Rong ; Cao, Weiguo ; Li, Lei ; Chen, Sheng ; Jiang, Xufeng ; Yi, Hongmei ; Song, Qi ; Wang, Li ; Cheng, Shu ; Xu, Pengpeng ; Yang, Xuanming ; Zhu, Yuxiang ; Xu, Xikang ; Wang, Fuzhe ; Li, Jianyong ; Zhao, Wei Li</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2024-198296</identifier><language>eng</language><ispartof>Blood, 2024-11, Vol.144 (Supplement 1), p.4822-4822</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sheng, Lingshuang</creatorcontrib><creatorcontrib>Yan, Zixun</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Zhang, Yilun</creatorcontrib><creatorcontrib>Shen, Rong</creatorcontrib><creatorcontrib>Cao, Weiguo</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Chen, Sheng</creatorcontrib><creatorcontrib>Jiang, Xufeng</creatorcontrib><creatorcontrib>Yi, Hongmei</creatorcontrib><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Cheng, Shu</creatorcontrib><creatorcontrib>Xu, Pengpeng</creatorcontrib><creatorcontrib>Yang, Xuanming</creatorcontrib><creatorcontrib>Zhu, Yuxiang</creatorcontrib><creatorcontrib>Xu, Xikang</creatorcontrib><creatorcontrib>Wang, Fuzhe</creatorcontrib><creatorcontrib>Li, Jianyong</creatorcontrib><creatorcontrib>Zhao, Wei Li</creatorcontrib><title>LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqdj0tOwzAURS0EEuGzAGZvCBKmz27aJszaAMogilDIhJFlGocEnDiy00reA4umH1bA6N7BPbo6hNwwfGAs4pMPbUxFOfKQsjji8fyEBGzGI4rI8ZQEiDinYbxg5-TCuS9EFk75LCA_2Tvi4h4k5GarNCz7saXJE0dIlgUtIVFaQ9koKwcPtbFQKC0Hpyo49NrK9Wish9VxmZuepqb6_G57yHw3NKaTcFtMCljRPM3uHneM2-jRQW1Nt3t9baRTwOBt3FT-ipzVUjt1_ZeXhL08l0lK19Y4Z1UtBtt20nrBUOy1xUFb7LXFUXv6H-YXC0penw</recordid><startdate>20241105</startdate><enddate>20241105</enddate><creator>Sheng, Lingshuang</creator><creator>Yan, Zixun</creator><creator>Wang, Li</creator><creator>Wu, Wen</creator><creator>Zhang, Yilun</creator><creator>Shen, Rong</creator><creator>Cao, Weiguo</creator><creator>Li, Lei</creator><creator>Chen, Sheng</creator><creator>Jiang, Xufeng</creator><creator>Yi, Hongmei</creator><creator>Song, Qi</creator><creator>Wang, Li</creator><creator>Cheng, Shu</creator><creator>Xu, Pengpeng</creator><creator>Yang, Xuanming</creator><creator>Zhu, Yuxiang</creator><creator>Xu, Xikang</creator><creator>Wang, Fuzhe</creator><creator>Li, Jianyong</creator><creator>Zhao, Wei Li</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241105</creationdate><title>LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study</title><author>Sheng, Lingshuang ; Yan, Zixun ; Wang, Li ; Wu, Wen ; Zhang, Yilun ; Shen, Rong ; Cao, Weiguo ; Li, Lei ; Chen, Sheng ; Jiang, Xufeng ; Yi, Hongmei ; Song, Qi ; Wang, Li ; Cheng, Shu ; Xu, Pengpeng ; Yang, Xuanming ; Zhu, Yuxiang ; Xu, Xikang ; Wang, Fuzhe ; Li, Jianyong ; Zhao, Wei Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1182_blood_2024_1982963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng, Lingshuang</creatorcontrib><creatorcontrib>Yan, Zixun</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Wu, Wen</creatorcontrib><creatorcontrib>Zhang, Yilun</creatorcontrib><creatorcontrib>Shen, Rong</creatorcontrib><creatorcontrib>Cao, Weiguo</creatorcontrib><creatorcontrib>Li, Lei</creatorcontrib><creatorcontrib>Chen, Sheng</creatorcontrib><creatorcontrib>Jiang, Xufeng</creatorcontrib><creatorcontrib>Yi, Hongmei</creatorcontrib><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Cheng, Shu</creatorcontrib><creatorcontrib>Xu, Pengpeng</creatorcontrib><creatorcontrib>Yang, Xuanming</creatorcontrib><creatorcontrib>Zhu, Yuxiang</creatorcontrib><creatorcontrib>Xu, Xikang</creatorcontrib><creatorcontrib>Wang, Fuzhe</creatorcontrib><creatorcontrib>Li, Jianyong</creatorcontrib><creatorcontrib>Zhao, Wei Li</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng, Lingshuang</au><au>Yan, Zixun</au><au>Wang, Li</au><au>Wu, Wen</au><au>Zhang, Yilun</au><au>Shen, Rong</au><au>Cao, Weiguo</au><au>Li, Lei</au><au>Chen, Sheng</au><au>Jiang, Xufeng</au><au>Yi, Hongmei</au><au>Song, Qi</au><au>Wang, Li</au><au>Cheng, Shu</au><au>Xu, Pengpeng</au><au>Yang, Xuanming</au><au>Zhu, Yuxiang</au><au>Xu, Xikang</au><au>Wang, Fuzhe</au><au>Li, Jianyong</au><au>Zhao, Wei Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study</atitle><jtitle>Blood</jtitle><date>2024-11-05</date><risdate>2024</risdate><volume>144</volume><issue>Supplement 1</issue><spage>4822</spage><epage>4822</epage><pages>4822-4822</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><doi>10.1182/blood-2024-198296</doi></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2024-11, Vol.144 (Supplement 1), p.4822-4822
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2024_198296
source ScienceDirect®
title LY007, a Novel Anti-CD20 CAR-T Cell Therapy for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (R/R B-NHL): Results from a Phase 1 Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A04%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LY007,%20a%20Novel%20Anti-CD20%20CAR-T%20Cell%20Therapy%20for%20Relapsed%20or%20Refractory%20B%20Cell%20Non-Hodgkin%20Lymphoma%20(R/R%20B-NHL):%20Results%20from%20a%20Phase%201%20Study&rft.jtitle=Blood&rft.au=Sheng,%20Lingshuang&rft.date=2024-11-05&rft.volume=144&rft.issue=Supplement%201&rft.spage=4822&rft.epage=4822&rft.pages=4822-4822&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2024-198296&rft_dat=%3Ccrossref%3E10_1182_blood_2024_198296%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-crossref_primary_10_1182_blood_2024_1982963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true